Fructose metabolism and metabolic disease

Journal of Clinical Investigation

Volumn 128, Issue 2, 2018, Pages 545-555

  Hannou, Sarah A ^a   Haslam, Danielle E ^b   McKeown, Nicola M ^b   Herman, Mark A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSE; CARBOHYDRATE; GLUCOSE; GLUCOSE TRANSPORTER 2; SLC2A2 PROTEIN, HUMAN;

APPETITE; FRUCTOSE ABSORPTION; FRUCTOSE METABOLISM; GASTROINTESTINAL ABSORPTION; GENETICS; GLUCOSE HOMEOSTASIS; HUMAN; LIPID HOMEOSTASIS; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; GENE EXPRESSION PROFILING; HYPERTENSION; LIVER; METABOLIC SYNDROME X; METABOLISM; RISK FACTOR;

ADIPOSITY; ANIMALS; FRUCTOSE; GENE EXPRESSION PROFILING; GLUCOSE; GLUCOSE TRANSPORTER TYPE 2; HUMANS; HYPERTENSION; LIVER; METABOLIC SYNDROME; RISK FACTORS; SUGARS;

EID: 85041470176     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI96702     Document Type: Review

References (193)

1. Kit BK, Fakhouri TH, Park S, Nielsen SJ, Ogden CL. Trends in sugar-sweetened beverage consumption among youth and adults in the United States: 1999–2010. Am J Clin Nutr. 2013;98(1):180–188.
2. Office of Disease Prevention and Health Promotion. Dietary Guidelines for Americans 2015–2020. ODPHP Website. http://health.gov/dietaryguidelines/2015/guidelines/. Accessed December 12, 2017.
3. Rosinger A, Herrick K, Gahche J, Park S. Sugar-sweetened beverage consumption among U.S. youth, 2011–2014. NCHSDataBrief. 2017(271):1–8.
4. Vos MB, et al. Added sugars and cardiovascular disease risk in children: a scientific statement from the American Heart Association. Circulation. 2017;135(19):e1017–e1034.
5. Khan TA, Sievenpiper JL. Controversies about sugars: results from systematic reviews and meta-analyses on obesity, cardiometabolic disease and diabetes. Eur J Nutr. 2016;55(suppl 2):25–43.
6. Ter Horst KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9(9):E981.
7. Stanhope KL. Sugar consumption, metabolic disease and obesity: the state of the controversy. Crit Rev Clin Lab Sci. 2016;53(1):52–67.
8. Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis. Am J Clin Nutr. 2013;98(4):1084–1102.
9. Ma J, McKeown NM, Hwang SJ, Hoffmann U, Jacques PF, Fox CS. Sugar-sweetened beverage consumption is associated with change of visceral adipose tissue over 6 years of follow-up. Circulation. 2016;133(4):370–377.
10. Maersk M, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012;95(2):283–289.
11. Green AK, Jacques PF, Rogers G, Fox CS, Meigs JB, McKeown NM. Sugar-sweetened beverages and prevalence of the metabolically abnormal phenotype in the Framingham Heart Study. Obesity (Silver Spring). 2014;22(5):E157–E163.
12. Imamura F, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 2015;351:h3576.
13. de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, Hu FB. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. Circulation. 2012;125(14):1735–1741.
14. Hert KA, Fisk PS, Rhee YS, Brunt AR. Decreased consumption of sugar-sweetened beverages improved selected biomarkers of chronic disease risk among US adults: 1999 to 2010. Nutr Res. 2014;34(1):58–65.
15. Dhingra R, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation. 2007;116(5):480–488.
16. Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 2009;89(4):1037–1042.
17. Jayalath VH, et al. Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts. Am J Clin Nutr. 2015;102(4):914–921.
18. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
19. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991;121(4 pt 2):1283–1288.
20. Stanhope KL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119(5):1322–1334.
21. Kuzma JN, et al. No differential effect of beverages sweetened with fructose, high-fructose corn syrup, or glucose on systemic or adipose tissue inflammation in normal-weight to obese adults: a randomized controlled trial. Am J Clin Nutr. 2016;104(2):306–314.
22. Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr. 2009;139(6):1228S–1235S.
23. Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100(3):833–849.
24. Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. Nutrition. 2014;30(5):503–510.
25. Stanhope KL, et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015;101(6):1144–1154.
26. Campos VC, Tappy L. Physiological handling of dietary fructose-containing sugars: implications for health. Int J Obes (Lond). 2016;40(suppl 1):S6–S11.
27. Stanhope KL, Schwarz JM, Havel PJ. Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol. 2013;24(3):198–206.
28. Patel C, Douard V, Yu S, Gao N, Ferraris RP. Transport, metabolism, and endosomal trafficking-dependent regulation of intestinal fructose absorption. FASEB J. 2015;29(9):4046–4058.
29. Barone S, et al. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J Biol Chem. 2009;284(8):5056–5066.
30. Gibson PR, Newnham E, Barrett JS, Shepherd SJ, Muir JG. Review article: Fructose malabsorption and the bigger picture. AlimentPharmacolTher. 2007;25(4):349–363.
31. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc. 2009;109(7):1204–1214.
32. Rumessen JJ. Fructose and related food carbohydrates. Sources, intake, absorption, and clinical implications. Scand J Gastroenterol. 1992;27(10):819–828.
33. Rumessen JJ, Gudmand-Høyer E. Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosac-charides. Gut. 1986;27(10):1161–1168.
34. Skoog SM, Bharucha AE. Dietary fructose and gastrointestinal symptoms: a review. Am J Gastroenterol. 2004;99(10):2046–2050.
35. Ferraris RP. Dietary and developmental regulation of intestinal sugar transport. Biochem J. 2001;360(pt 2):265–276.
36. Dotimas JR, et al. Diabetes regulates fructose absorption through thioredoxin-interacting protein. Elife. 2016;5:e18313.
37. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A. 2004;101(19):7281–7286.
38. Kim M, et al. Intestinal, but not hepatic, ChREBP is required for fructose tolerance. JCI Insight. 2017;2(24):e96703.
39. Sugimoto K, et al. Lowering of postprandial hyperfructosemia in humans by eucalyptus leaf extract: a randomized, double-blind, placebo-controlled crossover study. FoodSciTechnolRes. 2010;16(5):509–512.
40. Wahjudi PN, Patterson ME, Lim S, Yee JK, Mao CS, Lee WN. Measurement of glucose and fructose in clinical samples using gas chromatography/mass spectrometry. Clin Biochem. 2010; 43(1–2):198–207.
41. Preston GM, Calle RA. Elevated serum sorbitol and not fructose in type 2 diabetic patients. Bio-markInsights. 2010;5:33–38.
42. Lam P. Effects of consuming dietary fructose versus glucose on de novo lipogenesis in overweight and obese human subjects. Berkeley Scientific Journal. https://escholarship.org/uc/item/7vv7z7zw.
43. Tappy L, Lê KA. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clin Res Hepatol Gastroenterol. 2012;36(6):554–560.
44. Sugimoto K, et al. Eucalyptus leaf extract suppresses the postprandial elevation of portal, cardiac and peripheral fructose concentrations after sucrose ingestion in rats. J Clin Biochem Nutr. 2010;46(3):205–211.
45. Manolescu AR, Witkowska K, Kinnaird A, Cess-ford T, Cheeseman C. Facilitated hexose transporters: new perspectives on form and function. Physiology (Bethesda). 2007;22:234–240.
46. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3–9.
47. Karim S, Adams DH, Lalor PF. Hepatic expression and cellular distribution of the glucose transporter family. World J Gastroenterol. 2012;18(46):6771–6781.
48. Debosch BJ, Chen Z, Saben JL, Finck BN, Moley KH. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macroste-atosis. JBiolChem. 2014;289(16):10989–10998.
49. Boscá L, Corredor C. Is phosphofructokinase the rate-limiting step of glycolysis? Trends Biochem Sci. 1984;9(9):372–373.
50. Hers HG, Van Schaftingen E. Fructose 2,6-bis-phosphate 2 years after its discovery. Biochem J. 1982;206(1):1–12.
51. Sestoft L, Fleron P. Determination of the kinetic constants of fructose transport and phosphorylation in the perfused rat liver. Biochim Biophys Acta. 1974;345(1):27–38.
52. Björkman O, Felig P. Role of the kidney in the metabolism of fructose in 60-hour fasted humans. Diabetes. 1982;31(6 pt 1):516–520.
53. Sahebjami H, Scalettar R. Effects of fructose infusion on lactate and uric acid metabolism. Lancet. 1971;1(7695):366–369.
54. Burch HB, Max P, Ghyu K, Lowry OH. Metabolic intermediates in liver of rats given large amounts of fructose or dihydroxyacetone. Biochem Biophys Res Commun. 1969;34(5):619–626.
55. Topping DL, Mayes PA. Comparative effects of fructose and glucose on the lipid and carbohydrate metabolism of perfused rat liver. Br J Nutr. 1976;36(1):113–126.
56. Mavrias DA, Mayer RJ. Metabolism of fructose in the small intestine. 1. The effect of fructose feeding on fructose transport and metabolism in rat small intestine. Biochim Biophys Acta. 1973;291(2):531–537.
57. Ginsburg V, Hers HG. On the conversion of fructose to glucose by Guinea pig intestine. Biochim Biophys Acta. 1960;38:427–434.
58. Rand EB, Depaoli AM, Davidson NO, Bell GI, Burant CF. Sequence, tissue distribution, and functional characterization of the rat fructose transporter GLUT5. Am J Physiol. 1993; 264(6 pt 1):G1169–G1176.
59. Cui XL, Soteropoulos P, Tolias P, Ferraris RP. Fructose-responsive genes in the small intestine of neonatal rats. PhysiolGenomics. 2004;18(2):206–217.
60. Patel C, Douard V, Yu S, Tharabenjasin P, Gao N, Ferraris RP. Fructose-induced increases in expression of intestinal fructolytic and gluconeogenic genes are regulated by GLUT5 and KHK. Am J Physiol Regul Integr Comp Physiol. 2015;309(5):R499–R509.
61. Bismut H, Hers HG, Van Schaftingen E. Conversion of fructose to glucose in the rabbit small intestine. A reappraisal of the direct pathway. Eur JBiochem. 1993;213(2):721–726.
62. Holdsworth CD, ed. Sugars in Nutrition. New York, New York, USA: Raven Press; 1991.
63. Brown KS, Kalinowski SS, Megill JR, Durham SK, Mookhtiar KA. Glucokinase regulatory protein May interact with glucokinase in the hepatocyte nucleus. Diabetes. 1997;46(2):179–186.
64. Niculescu L, Veiga-da-Cunha M, Van Schaftingen E. Investigation on the mechanism by which fructose, hexitols and other compounds regulate the translocation of glucokinase in rat hepatocytes. Biochem J. 1997;321(pt 1):239–246.
65. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008;414(1):1–18.
66. McGuinness OP, Cherrington AD. Effects of fructose on hepatic glucose metabolism. Curr Opin Clin Nutr Metab Care. 2003;6(4):441–448.
67. Thurston JH, Jones EM, Hauhart RE. Decrease and inhibition of liver glycogen phosphorylase after fructose. An experimental model for the study of hereditary fructose intolerance. Diabetes. 1974;23(7):597–604.
68. Van Den Berghe G, Hue L, Hers HG. Effect of administration of the fructose on the glycogeno-lytic action of glucagon. An investigation of the pathogeny of hereditary fructose intolerance. Biochem J. 1973;134(2):637–645.
69. Eggleston LV, Woods HF. Activation of liver pyruvate kinase by fructose-1-phosphate. FEBS Lett. 1970;6(1):43–45.
70. Niewoehner CB, Gilboe DP, Nuttall GA, Nuttall FQ. Metabolic effects of oral fructose in the liver of fasted rats. Am J Physiol. 1984; 247(4 pt 1):E505–E512.
71. Van Schaftingen E. A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phos-phate and fructose 1-phosphate. Eur J Biochem. 1989;179(1):179–184.
72. Lanaspa MA, Tapia E, Soto V, Sautin Y, Sánchez-Lozada LG. Uric acid and fructose: potential biological mechanisms. Semin Nephrol. 2011;31(5):426–432.
73. van den Berghe G, Bronfman M, Vanneste R, Hers HG. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. A kinetic study of liver adenylate deaminase. Biochem J. 1977;162(3):601–609.
74. Raivio KO, Becker MA, Meyer LJ, Greene ML, Nuki G, Seegmiller JE. Stimulation of human purine synthesis de novo by fructose infusion. Metab Clin Exp. 1975;24(7):861–869.
75. Jamnik J, et al. Fructose intake and risk of gout and Hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2016;6(10):e013191.
76. Chang CH, et al. Relationship between Hyperuricemia (HUC) and metabolic syndrome (MS) in institutionalized elderly men. ArchGerontol Geriatr. 2009;49(suppl 2):S46–S49.
77. Liu M, et al. Association between serum uric acid level and metabolic syndrome and its sex difference in a Chinese community elderly population. Int J Endocrinol. 2014;2014:754678.
78. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol. 2008;20(2):187–191.
79. Lanaspa MA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. JBiol Chem. 2012;287(48):40732–40744.
80. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584–C596.
81. Tapia E, et al. Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats. Am J Physiol Renal Physiol. 2013;304(6):F727–F736.
82. Choi YJ, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197–3204.
83. Lanaspa MA, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One. 2012;7(10):e47948.
84. Li X, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ. 2017;357:j2376.
85. Belfiore F, Romeo F, Iannello S, Salamone C. The glucose-6-phosphatase/glucokinase ratio in the liver of obese-diabetic subjects. Biochem Med Metab Biol. 1989;41(1):77–80.
86. Huupponen R, Karvonen I, Sotaniemi E. Activity of hepatic glucose phosphorylating and NADPH generating enzymes in Zucker rats. Diabetes Res. 1989;10(3):143–146.
87. Bonthron DT, Brady N, Donaldson IA, Stein-mann B. Molecular basis of essential fructosuria: molecular cloning and mutational analysis of human ketohexokinase (fructokinase). Hum Mol Genet. 1994;3(9):1627–1631.
88. Hayward BE, Bonthron DT. Structure and alternative splicing of the ketohexokinase gene. Eur J Biochem. 1998;257(1):85–91.
89. Diggle CP, et al. Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J Histochem Cytochem. 2009;57(8):763–774.
90. Asipu A, Hayward BE, O’Reilly J, Bonthron DT. Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes. 2003;52(9):2426–2432.
91. Ishimoto T, et al. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc Natl Acad Sci U S A. 2012;109(11):4320–4325.
92. Steinitz H, Mizrahy O. Essential fructosuria and hereditary fructose intolerance. N Engl J Med. 1969;280(4):222.
93. Softic S, et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest. 2017;127(11):4059–4074.
94. Mirtschink P, et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature. 2015;522(7557):444–449.
95. Li X, et al. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol. 2016;18(5):561–571.
96. Hers HG, Joassin G. [Anomaly of hepatic aldolase in intolerance to fructose]. Enzymol Biol Clin (Basel). 1961;1:4–14.
97. Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet. 1998;35(5):353–365.
98. Oppelt SA, Sennott EM, Tolan DR. Aldolase-B knockout in mice phenocopies hereditary fructose intolerance in humans. MolGenetMetab. 2015;114(3):445–450.
99. Lanaspa MA, et al. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun. 2013;4:2434.
100. Oates PJ. Polyol pathway and diabetic peripheral Neuropathy. Int Rev Neurobiol. 2002;50:325–392.
101. Hwang JJ, et al. The human brain produces fructose from glucose. JCIInsight. 2017;2(4):e90508.
102. Cheng HM, González RG. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. MetabClinExp. 1986;35(4 suppl 1):10–14.
103. Jedziniak JA, Chylack LT Jr., Cheng HM, Gillis MK, Kalustian AA, and Tung WH. The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase. Invest Ophthalmol Vis Sci. 1981;20(3):314–326.
104. Frenette G, Thabet M, Sullivan R. Polyol pathway in human epididymis and semen. JAndrol. 2006;27(2):233–239.
105. Martini AC, et al. Overweight and seminal quality: a study of 794 patients. FertilSteril. 2010;94(5):1739–1743.
106. Jayaraman V, Ghosh S, Sengupta A, Srivastava S, Sonawat HM, Narayan PK. Identification of biochemical differences between different forms of male infertility by nuclear magnetic resonance (NMR) spectroscopy. J Assist Reprod Genet. 2014;31(9):1195–1204.
107. Hwang JJ, et al. Fructose levels are markedly elevated in cerebrospinal fluid compared to plasma in pregnant women. PLoSOne. 2015;10(6):e0128582.
108. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007;2007:61038.
109. Mathebula SD. Polyol pathway: a possible mechanism of diabetes complications in the eye. Afr Vision Eye Health. 2015;74(1):Art. #13.
110. La Vignera S, Condorelli R, Vicari E, D’Agata R, Calogero AE. Diabetes mellitus and sperm parameters. JAndrol. 2012;33(2):145–153.
111. Das B, Srivastava SK. Activation of aldose reductase from human tissues. Diabetes. 1985;34(11):1145–1151.
112. Lanaspa MA, et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol. 2014;25(11):2526–2538.
113. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–585.
114. Sobrecases H, et al. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab. 2010;36(3):244–246.
115. Hudgins LC, Parker TS, Levine DM, Hellerstein MK. A dual sugar challenge test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab. 2011;96(3):861–868.
116. Topping DL, Mayes PA. The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism. Biochem J. 1972;126(2):295–311.
117. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Annu Rev Nutr. 1996;16:523–557.
118. Parks EJ, Skokan LE, Timlin MT, Dingfelder CS. Dietary sugars stimulate fatty acid synthesis in adults. J Nutr. 2008;138(6):1039–1046.
119. Zavaroni I, Chen YD, Reaven GM. Studies of the mechanism of fructose-induced hypertriglyceridemia in the rat. Metab Clin Exp. 1982;31(11):1077–1083.
120. Crescenzo R, Bianco F, Falcone I, Coppola P, Liv-erini G, Iossa S. Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose. Eur J Nutr. 2013;52(2):537–545.
121. McGarry JD. Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51(1):7–18.
122. Herman MA, Samuel VT. The sweet path to metabolic demise: fructose and lipid synthesis. Trends EndocrinolMetab. 2016;27(10):719–730.
123. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A. 2010;107(8):3441–3446.
124. Peterson TR, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146(3):408–420.
125. Haas JT, et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. CellMetab. 2012;15(6):873–884.
126. Koo HY, Miyashita M, Cho BH, Nakamura MT. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem Biophys Res Commun. 2009;390(2):285–289.
127. Kammoun HL, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. JClin Invest. 2009;119(5):1201–1215.
128. Flamment M, Hajduch E, Ferré P, Foufelle F. New insights into ER stress-induced insulin resistance. TrendsEndocrinolMetab. 2012;23(8):381–390.
129. Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science. 2008;320(5882):1492–1496.
130. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006;4(2):107–110.
131. Benhamed F, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. JClin Invest. 2012;122(6):2176–2194.
132. Boergesen M, Poulsen Ll, Schmidt SF, Frigerio F, Maechler P, Mandrup S. ChREBP mediates glucose repression of peroxisome proliferator-activated receptor alpha expression in pancreatic beta-cells. JBiolChem. 2011;286(15):13214–13225.
133. Kim MS, et al. ChREBP regulates fructose-induced glucose production independently of insulin signaling. JClinInvest. 2016;126(11):4372–4386.
134. Herman MA, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature. 2012;484(7394):333–338.
135. Dentin R, et al. Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver. J Hepatol. 2012;56(1):199–209.
136. Filhoulaud G, Guilmeau S, Dentin R, Girard J, Postic C. Novel insights into ChREBP regulation and function. TrendsEndocrinolMetab. 2013;24(5):257–268.
137. Baraille F, Planchais J, Dentin R, Guilmeau S, Postic C. Integration of ChREBP-mediated glucose sensing into whole body metabolism. Physiology (Bethesda). 2015;30(6):428–437.
138. Erion DM, et al. The role of the carbohydrate response element-binding protein in male fructose-fed rats. Endocrinology. 2013;154(1):36–44.
139. Kooner JS, et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet. 2008;40(2):149–151.
140. Kathiresan S, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. NatGenet. 2008;40(2):189–197.
141. Taskinen MR, et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J Intern Med. 2017;282(2):187–201.
142. Donnelly KL, Smith CI, Schwarzenberg SJ, Jes-surun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–1351.
143. Caron S, et al. Transcriptional activation of apolipoprotein CIII expression by glucose May contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31(3):513–519.
144. Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/beta-trophin in human type 2 diabetes and obesity. Sci Rep. 2014;4:5013.
145. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. JBiolChem. 2002;277(3):1645–1648.
146. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. CellMetab. 2005;1(6):361–370.
147. Lin J, et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP. Cell. 2005;120(2):261–273.
148. Chambers KT, et al. PGC-1β and ChREBP partner to cooperatively regulate hepatic lipogenesis in a glucose concentration-dependent manner. Mol Metab. 2013;2(3):194–204.
149. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat RevGastroenterolHepatol. 2010;7(5):251–264.
150. Chan SM, et al. Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes. 2013;62(6):2095–2105.
151. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol. 2011;54(4):795–809.
152. Zhang D, et al. Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. JClin Invest. 2017;127(7):2855–2867.
153. Curry DL. Effects of mannose and fructose on the synthesis and secretion of insulin. Pancreas. 1989;4(1):2–9.
154. Adams SH, Stanhope KL, Grant RW, Cummings BP, Havel PJ. Metabolic and endocrine profiles in response to systemic infusion of fructose and glucose in rhesus macaques. Endocrinology. 2008;149(6):3002–3008.
155. Blakely SR, Hallfrisch J, Reiser S, Prather ES. Long-term effects of moderate fructose feeding on glucose tolerance parameters in rats. J Nutr. 1981;111(2):307–314.
156. Beck-Nielsen H, Pedersen O, Lindskov HO. Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr. 1980;33(2):273–278.
157. Ter Horst KW, Schene MR, Holman R, Romijn JA, Serlie MJ. Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials. Am J Clin Nutr. 2016;104(6):1562–1576.
158. Nagai Y, et al. The role of peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC-1β) in the pathogenesis of fructose-induced insulin resistance. CellMetab. 2009;9(3):252–264.
159. Samuel VT, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. JBiolChem. 2004;279(31):32345–32353.
160. Kumashiro N, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc NatlAcadSciUSA. 2011;108(39):16381–16385.
161. Farese RV Jr., Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. CellMetab. 2012;15(5):570–573.
162. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. NatMed. 2017;23(7):804–814.
163. Templeman NM, et al. Reduced circulating insulin enhances insulin sensitivity in old mice and extends lifespan. CellRep. 2017;20(2):451–463.
164. Davis JD. The effectiveness of some sugars in stimulating licking behavior in the rat. Physiol Behav. 1973;11(1):39–45.
165. Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol. 2007;15(5):481–491.
166. Wideman CH, Nadzam GR, Murphy HM. Implications of an animal model of sugar addiction, withdrawal and relapse for human health. Nutr Neurosci. 2005;8(5–6):269–276.
167. Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Opiate-like effects of sugar on gene expression in reward areas of the rat brain. Brain Res Mol Brain Res. 2004;124(2):134–142.
168. Tellez LA, et al. Separate circuitries encode the hedonic and nutritional values of sugar. Nat Neurosci. 2016;19(3):465–470.
169. Shapiro A, Mu W, Roncal C, Cheng KY, Johnson RJ, Scarpace PJ. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol. 2008;295(5):R1370–R1375.
170. Chotiwat C, Sharp C, Teff K, Harris RBS. Feeding a high-fructose diet induces leptin resistance in rats. Appetite. 2007;49(1):284.
171. Teff KL, et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab. 2004;89(6):2963–2972.
172. Luo S, Monterosso JR, Sarpelleh K, Page KA. Differential effects of fructose versus glucose on brain and appetitive responses to food cues and decisions for food rewards. Proc Natl Acad Sci U S A. 2015;112(20):6509–6514.
173. Page KA, et al. Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. JAMA. 2013;309(1):63–70.
174. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic States. Cell Metab. 2007;5(6):426–437.
175. Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2015;4(1):51–57.
176. Inagaki T, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–425.
177. Sánchez J, Palou A, Picó C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. Endocrinology. 2009;150(12):5341–5350.
178. Laeger T, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014;124(9):3913–3922.
179. Dushay J, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456–463.
180. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. DiabetesCare. 2009;32(8):1542–1546.
181. Fisher FM, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781–2789.
182. Iizuka K, Takeda J, Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBSLett. 2009;583(17):2882–2886.
183. Fisher FM, et al. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. MolMetab. 2017;6(1):14–21.
184. von Holstein-Rathlou S, et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. CellMetab. 2016;23(2):335–343.
185. Talukdar S, et al. FGF21 regulates sweet and alcohol preference. CellMetab. 2016;23(2):344–349.
186. Tanaka T, et al. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. Am J Clin Nutr. 2013;97(6):1395–1402.
187. Chu AY, et al. Novel locus including FGF21 is associated with dietary macronutrient intake. Hum Mol Genet. 2013;22(9):1895–1902.
188. Singh AK, et al. Fructose-induced hypertension: essential role of chloride and fructose absorbing transporters PAT1 and Glut5. Kidney Int. 2008;74(4):438–447.
189. Johnson RJ, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–1190.
190. World Health Organization. Guideline: Sugars Intake For Adults and Children. WHO Website. http://www.who.int/nutrition/publications/guidelines/sugars_intake/en/. Accessed December 12, 2017.
191. Johnson RK, et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2009;120(11):1011–1020.
192. Batis C, Rivera JA, Popkin BM, Taillie LS. First-year evaluation of Mexico’s tax on nonessential energy-dense foods: an observational study. PLoS Med. 2016;13(7):e1002057.
193. Falbe J, Thompson HR, Becker CM, Rojas N, McCulloch CE, Madsen KA. Impact of the Berkeley excise tax on sugar-sweetened beverage consumption. Am J Public Health. 2016;106(10):1865–1871.